Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: citric acid; xanthan gum; aspartame; methyl hydroxybenzoate; purified water; silicon dioxide; sorbitol; lecithin; sodium citrate dihydrate; flavour - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 500 mg - injection, powder for - excipient ingredients: polysorbate 80; sodium hydroxide; citric acid; hydrochloric acid - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - clonazepam -

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - alectinib hydrochloride, quantity: 161.33 mg (equivalent: alectinib, qty 150 mg) - capsule, hard - excipient ingredients: magnesium stearate; potassium chloride; carmellose calcium; maize starch; carnauba wax; hypromellose; hyprolose; titanium dioxide; lactose monohydrate; sodium lauryl sulfate; carrageenan; iron oxide red; iron oxide yellow; indigo carmine aluminium lake; shellac; glyceryl monooleate - alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive, locally advanced or metastatic non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - obinutuzumab, quantity: 1000 mg - injection, concentrated - excipient ingredients: poloxamer; histidine hydrochloride monohydrate; trehalose dihydrate; water for injections; histidine - chronic lymphocytic leukaemia,gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll).,follicular lymphoma,gazyva in combination with chemotherapy followed by gazyva maintenance is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.,gazyva in combination with bendamustine, followed by gazyva maintenance, is indicated for the treatment of patients with follicular lymphoma (fl) who did not respond to, or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.,pre-treatment to reduce the risk of cytokine release syndrome (crs) induced by glofitamab,gazyva is indicated as a pre-treatment to reduce the risk of cytokine release syndrome (crs) induced by glofitamab.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: threonine; polysorbate 20; urea; water for injections; dibasic sodium phosphate dodecahydrate; glutamic acid; leucine; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; phenylalanine; glycine; isoleucine - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 20000 iu/ml - injection - excipient ingredients: polysorbate 20; monobasic sodium phosphate; sodium chloride; urea; isoleucine; glycine; threonine; calcium chloride dihydrate; glutamic acid; dibasic sodium phosphate dodecahydrate; phenylalanine; leucine; water for injections - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: glutamic acid; leucine; isoleucine; polysorbate 20; water for injections; dibasic sodium phosphate dodecahydrate; urea; monobasic sodium phosphate; phenylalanine; threonine; calcium chloride dihydrate; glycine; sodium chloride - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 13333.33 iu/ml - injection - excipient ingredients: leucine; phenylalanine; polysorbate 20; glycine; urea; water for injections; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; threonine; glutamic acid; isoleucine; dibasic sodium phosphate dodecahydrate - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 10000 iu/ml - injection - excipient ingredients: monobasic sodium phosphate; glycine; polysorbate 20; leucine; threonine; water for injections; isoleucine; calcium chloride dihydrate; phenylalanine; urea; glutamic acid; dibasic sodium phosphate dodecahydrate; sodium chloride - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.